Verici Dx Plc
Research Verici Dx Plc (VRCI) on Bullrun: market cap GBX 514.65M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVRCI
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyGBX
- Market capGBX 514.65M
- Financial periodFY2025
- RevenueUSD 3.66M
- Revenue growth9.7%
- Net income-USD 6.93M
- Free cash flow-USD 8.45M
- Gross margin77.5%
Valuation Snapshot
latest market cap is GBX 514.65M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 3.66M | -USD 6.93M | -USD 8.45M | 77.5% | -0.01 | USD 3.34M | USD 197.00K | USD 6.51M |
| FY2024 | USD 3.34M | -USD 5.87M | -USD 6.21M | n/a | -0.03 | USD 4.06M | USD 371.00K | USD 5.27M |
| FY2023 | USD 1.01M | -USD 8.73M | -USD 7.39M | n/a | -0.05 | USD 2.65M | USD 540.00K | USD 3.56M |
| FY2022 | USD 0 | -USD 11.41M | -USD 11.38M | n/a | -0.07 | USD 9.81M | USD 700.00K | USD 11.51M |
| FY2021 | USD 0 | -USD 8.33M | -USD 7.30M | n/a | -0.06 | USD 10.34M | USD 0 | USD 11.99M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-29 | GBX 514.65M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 GBX.
About Verici Dx Plc
Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; Clarava, a pre-transplant prognosis test for the risk of early acute rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Verici Dx Plc's market cap?
Verici Dx Plc's market capitalization is GBX 514.65M.
What does Verici Dx Plc do?
Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; Clarava, a pre-transplant prognosis test for the risk of early acute rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure.